MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ...
Telix’s Illuccix prostate cancer PSMA-PET imaging agent approved in the Netherlands: Melbourne, Australia Wednesday, March 19, 2025, 12:00 Hrs [IST] Telix, a biopharmaceutical c ...
1d
Medical Device Network on MSNTelix’s prostate cancer imaging agent approved in BrazilBrazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer ...
Melbourne-based biotech Telix Pharmaceuticals has announced that its prostate cancer diagnostic agent Illuccix has been ...
Telix’s strategy revolves around expanding its Illuccix distribution and investing in its product pipeline. Illuccix launched in April 2022 and was the second commercially available PSMA imaging ...
Illuccix, after radiolabelling with gallium-68, is indicated in Norway for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa ...
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results